In a significant development for investors, Haemonetics Corporation (NYSE: HAE) received a “Buy” rating from Craig Bijou at BofA Securities on May 22, 2026. This upgrade comes with an ambitious price target of $80, suggesting a substantial upside potential from the current trading price of $61.94. This positive outlook reflects not only the company’s financial health but also an overall confidence among analysts in its ability to outperform the market amid ongoing volatility.
Recent Price Action
Haemonetics has displayed noteworthy movements in its stock price, closing at $61.94, up $2.49 or approximately 4.02%. In recent trading sessions, HAE demonstrated resilience as it approached its 52-week high of $90.66, although this is still $28.72 below the peak. Conversely, the stock has seen fluctuations, with a low of $31.54 within the same period. With a market capitalization of $2.99 billion and a beta of 0.529, HAE’s relatively low volatility suggests that it may offer a safer investment in a tumultuous market landscape. On the trading front, the stock recorded a volume of 301,724 shares, substantially below its average volume of 774,088, indicating some caution among traders.
[chart type=’price’ value=’HAE’]
Short- and Long-Term Performance
Examining Haemonetics’ stock performance reveals mixed results in the context of broader market trends. Over the past 30 days, the stock has struggled, returning -12.35%. However, this has been offset by a strong quarterly performance of 39.47%, suggesting a rebound. Year-to-date, HAE reflects a -4.66% return, emphasizing its struggles compared to a generally bullish market. The weekly volatility, pegged at 4.36%, and a lower monthly volatility of 2.62% indicate a period of consolidation as investors weigh the company’s prospects.
[chart type=’performance’ value=’HAE’]
Earnings / Financials
In its most recent earnings report on May 7, 2026, Haemonetics posted an earnings per share (EPS) of $1.29, slightly beating analyst expectations of $1.28, yielding a surprise factor of approximately 0.78%. This follows a previous EPS of $1.31 in February, exceeding estimates of $1.27 with a surprise of 3.15%. The consistent ability to surpass expectations reflects the company’s operational robustness and solid management, enhancing investor confidence in the firm’s financial trajectory.
[chart type=’income-bar-chart’ value=’HAE’]
Analyst / Consensus View
The consensus rating for Haemonetics has been relatively bullish, with five total ratings distributed as three “Buy,” two “Hold,” and no “Sell” recommendations. The average price target stands at $75.20, with the highest target set at $89. This unanimous positive sentiment suggests a strong belief in the company’s growth potential and resilience, particularly amid economic challenges. The recent upgrade to “Buy” from BofA Securities aligns with this outlook, positioning HAE as an attractive investment option moving forward.
[chart type=’analyst-ratings’ value=’HAE’]
Stock Grading or Fundamental View
The Stocks Telegraph grading score for Haemonetics Corporation is rated at 50, indicating a balanced but cautiously optimistic outlook in terms of overall health and investment viability. This score synthesizes various factors, including financial performance, market position, and innovation potential. The moderate rating denotes that while there are strengths, potential investors should remain cognizant of challenges that may impact long-term growth.
[chart type=’st-cards’ value=’HAE’]
Conclusion
For investors seeking a balanced mix of growth and stability, Haemonetics Corporation presents as an intriguing opportunity. The recent “Buy” rating from BofA Securities and the comparatively modest risk profile suggest suitability for those with a long-term investment horizon. Nevertheless, potential investors should be aware of the broader market volatility and the company’s previous performance inconsistencies. The stock deserves close attention, particularly as it navigates this dynamic economic landscape and aims to realize its price target of $80 in the future.